Concomitant Use of Methocarbamol and Tizanidine: Not Recommended
There is no evidence supporting the efficacy of combining methocarbamol and tizanidine, and this combination should be avoided due to additive central nervous system adverse effects without demonstrated additional benefit.
Evidence-Based Rationale
Lack of Combination Efficacy Data
No studies have evaluated the concomitant use of methocarbamol and tizanidine. The available evidence demonstrates that:
Skeletal muscle relaxants (SMRs) show no superiority over one another 1, 2. Systematic reviews consistently find insufficient evidence to determine that any single SMR is more effective than another for musculoskeletal conditions.
Recent high-quality evidence shows SMRs provide no benefit over placebo when combined with NSAIDs for acute low back pain 3. In a 2022 analysis of 4 randomized trials comparing 7 different SMRs (including both methocarbamol and tizanidine), none demonstrated statistically significant improvement over placebo when patients also received NSAIDs.
Individual Agent Efficacy
Tizanidine: Has fair evidence for efficacy in spasticity from multiple sclerosis and spinal cord injury 4, 2. For musculoskeletal conditions, evidence is limited but shows some benefit for neck pain 5. Maximum daily dose is 36 mg in divided doses 4.
Methocarbamol: Has very limited evidence for musculoskeletal conditions 2. One older 1975 study showed 60% response versus 30% with placebo 6, but this has not been replicated in modern trials. The 2022 comparative study found methocarbamol actually performed worse than other SMRs, with only 8.1-point RMDQ improvement versus 10.5 for placebo 3.
Safety Concerns with Combination Therapy
All SMRs cause dose-related CNS adverse effects, primarily sedation and dizziness 7, 1. Combining two agents would:
- Increase sedation risk without evidence of additive benefit
- Compound cognitive impairment, particularly problematic in older adults
- Increase fall risk, especially concerning given that baclofen (another SMR) shows higher injury rates than tizanidine in older adults 8
The 2007 ACP/APS guideline explicitly states that SMRs are "associated with central nervous system adverse effects (primarily sedation)" and notes "there is no compelling evidence that skeletal muscle relaxants differ in efficacy" 7.
Clinical Algorithm
For muscle spasm in adults:
First-line: NSAIDs or acetaminophen alone 7
If inadequate response: Add a single SMR for short-term use (≤2 weeks)
Never combine two SMRs - no evidence of benefit, clear evidence of additive harm
If single SMR fails: Reassess diagnosis, consider alternative therapies or referral 7, not combination SMR therapy
Key Pitfalls to Avoid
- Do not assume additive mechanisms equal additive benefit - the 2022 data show even single SMRs add nothing to NSAID therapy 3
- Avoid prolonged use - evidence supports only short-term (days to weeks) use 7, 5
- In older adults, prefer tizanidine over baclofen if an SMR is necessary, given lower injury/delirium risk 8, but avoid combinations entirely